LDS/Medical Tests/Muscular Dystrophies Gene Mutation Panel, NGS

Muscular Dystrophies Gene Mutation Panel, NGS

Muscular dystrophies are inherited neuromuscular diseases characterized by muscle weakness and wasting due to muscle dysfunction. Age of onset, severity, progression and histopathological findings are variable between the different subtypes of muscular dystrophies which include: Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, Myotonic dystrophy type 1, Myotonic dystrophy type 2 and Oculopharyngeal muscular dystrophy. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions.

Duchenne muscular dystrophy (DMD) is an x-linked genetic disorder seen almost exclusively in males and is characterized by progressive muscle atrophy beginning before age 5. Affected individuals have proximal skeletal weakness resulting in a waddling gait, difficulty in climbing stairs, running, jumping and standing from a seated position. Most individuals are wheelchair dependent by age 11 or 12. Serum creatine phosphokinase (CK) levels are 10x increased in virtually all patients. DMD patients typically develop dilated cardiomyopathy (DCM) by age 18 and death usually occurs from respiratory compromise and cardiomyopathy by the third decade. Over 5000 mutations in the dystrophin (DMD) gene at Xp21.2-p21.1 have been identified and include deletion of the entire gene, deletion or duplication of one or more exons, small insertion or deletions and single base pair changes. The incidence of DMD is approximately 1 in 3500 males.

Becker muscular dystrophy (BMD) typically has milder and more varied symptoms in comparison to DMD. Individuals with BMD have progressive muscle weakness, (proximal > distal), activity-induced cramping, and flexion contractures of the elbows. Most BMD patients are wheelchair bound by age 16 but many remain ambulatory until their 30’s. This form of muscular dystrophy differs from DMD in that patients retain strength in their neck flexor muscles. As with DMD, BMD patients have elevated serum CK levels (5x normal) and are affected by cardiomyopathy with males developing congestive heart failure by age 40. Like DMD, BMD is caused by mutations in the dystrophin (DMD) gene. The incidence of BMD in boys is approximately 1 in 18,500.

Emery-Dreifuss muscular dystrophy (EDMD) is another muscular dystrophy characterized by slowly progressive wasting and weakness. In most patients with EDMD, joint contractures affecting elbow flexors, achilles tendons and neck flexors appear in childhood. Cardiac involvement may be manifested with syncope, poor exercise tolerance, palpitations, cardiac rhythm disturbances and the eventual development of congestive heart failure secondary to cardiomyopathy. The x-linked forms of EDMD are caused by mutations in EMD (EDMD1: 8.5%) or FHL1 (EDMD6: 1.2%). The autosomal dominant form (EDMD2: 26.5%) and the rare autosomal recessive form (EDMD3) are caused by mutations in LMNA. In the remaining 63% of EDMD cases the genetic cause is unknown. The overall incidence of EDMD is 1:100,000 births.

Limb-girdle muscular dystrophy (LGMD) is a group of diseases that cause weakness and wasting of the skeletal muscles of the shoulders, pelvis and upper thighs The age at onset, severity and features are highly variable, even within the same kindred. Cardiomyopathy may occur in some forms of LGMD as well as breathing problem due to weakness of the respiratory musculature. LGMD affects both men and women and has estimated prevalence from 1/14,500 to 1/123,000. The disorder may be inherited as either an autosomal dominant (LGMD1), or autosomal recessive (LGMD2) condition. LGMD can be caused by mutations in a large number of genes encoding for: myotilin (MYOT; LGMD1A), lamin (LMNA; LGMD1B), caveolin (CAV3; LGMD1C), calpain (CAPN3; LGMD2A), dysferilin (DYSF; LGMD2B), and sarcoglycans (SGCA, SGCB, SGCG, SGCD; LGMD2C-2F).

Facioscapulohumeral muscular dystrophy (FSH), also known as Landouzy-Dejerine disease, is a disorder characterized by muscle weakness and wasting of facial muscles, eye muscles, shoulder girdle, hip girdle and dorsiflexors of the feet. Additionally, affected individuals may have exaggerated lumbar lordosis, high-tone hearing loss and abnormalities in retina. There are two types of FSH, in FSHD1 (95% of cases), a pathogenic contraction is present in the DAZ4 gene on chromosome 4 that reduces the number of repeats from the normal 11-100 to less than 10. Due to the contraction the gene is also hypomethylated. In FSHD2, hypomethylation of DAZ4 results from mutations in the SMCHD1 gene, which encodes for a protein that normally is responsible for the methylation of DAZ4.

Myotonic dystrophy type 1 (DM1, Steinert's disease) is an autosomal dominant disorder that affects skeletal and smooth muscle, as well as the eyes, heart, endocrine system, and central nervous system. DM1 is categorized into three overlapping phenotypes: mild, classic and congenital. The mild form is characterized by cataracts and mild myotonia. The classic type is characterized by muscle weakness, wasting, myotonia, cataracts and cardiac conduction abnormalities. Congenital DM1 presents at birth with generalized weakness and hypotonia. These infants commonly have intellectual disability, respiratory insufficiency and early death. DM1 is caused by a heterozygous trinucleotide repeat expansion (CTG)n in the DMPK gene on chromosome 19q13. Normal individuals have 5 to 34 repeats, premutation alleles have 35-49 repeats and pathogenic alleles have > 50 repeats. Disease severity varies with the size of the trinucleotide repeat expansion. Individuals with classic DM1 have 100 to 1,000 repeats, and those with congenital onset can have more than 2,000 repeats. DM1 affects approximately 1 in 20,000 people.

Myotonic dystrophy type 2 (DM2) is multisystem disorders that affect smooth and skeletal muscle and is one of the most common forms of muscular dystrophy. DM2 typically presents in the third decade or later with myotonia and muscle weakness or stiffness, but may also include generalized proximal weakness, cardiac conduction defects, cataracts, insulin-insensitivity, or testicular failure. Histologic findings include atrophic fibers with pyknotic myonuclei and marked proliferation of fibers with central nuclei. It is caused by mutation in CNBP gene (also known as ZNF9) that encodes a cellular nucleic acid-binding protein or CCHC-type zinc finger nucleic acid binding protein. DM2 is an autosomal dominant disorder caused by an expansion of the CCTG tetranucleotide repeat within the complex repeat motif [TG(n)TCTG(n)CCTG(n)] in intron 1 of the CNBP gene. The three repeating units (TG, TCTG, CCTG) within this motif are all highly variable in both individuals with DM2 and the general population. The CCTG repeat is the only repeat that expands to pathogenic lengths, although the highly polymorphic TG and TCTG repeats contribute to the overall length of the expansion. Normal alleles have 11-26 CCTG repeats and disease alleles have greater than 75 repeats. Disease alleles can contain more than 11,000 repeats and have an average of 5,000 repeats. DM2 affects at least 1 in 8,000 people worldwide.

Oculopharyngeal muscular dystrophy (OPMD) is a rare inherited muscular dystrophy that begins in adulthood, typically after age 40. It is characterized by weakness of the muscles in both eyelids that causes droopy eyelids (ptosis). Along with ptosis, affected individuals develop weakness of the throat muscles that causes difficulty swallowing (dysphagia). Individuals with OPMD also have weakness and wasting (atrophy) of the tongue, weakness in the shoulder muscles, upper legs, and hips (limb-girdle muscles). These individuals often also have disturbances in nerve function (neuropathy), a gradual loss of intellectual functioning (cognitive decline), and psychiatric symptoms such as depression or strongly held false beliefs (delusions). OPMD is caused by an expansion of a GCN trinucleotide repeat (N represent any of the 4 nucleotides) in the first exon of PABPN1. Normal alleles contain ten GCN trinucleotide repeats, while pathogenic alleles contain 11-17 repeats.

Panel Components:

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: CAPN3, CAV3 CAVIN1, CHKB, CRPPA, DAG1, DES, DMD, : DNAJB6, DPM1, DPM3 , DYSF, EMD , FHL1, FKRP, FKTN, GOSR2, ITGA7, LAMA2 , LARGE1 , LMNA, MMEL1 , MYOT, PNPLA2, POMGNT1, POMGNT2 , POMT1, 2 , SGCA, SGCB, SGCD, SGCG , SMN1, SMN2 , SYNE1, SYNE2, TCAP , TMEM43, TRIM32, TTN associated with muscular dystrophies.

  • Diagnostic confirmation of muscular dystrophies
  • Differential diagnosis of muscular dystrophies: myotonic dystrophy, type II (DM2) from type I (DM1), Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy and Oculopharyngeal muscular dystrophy
  • Carrier screening in family member at risk for muscular dystrophies
  • Prenatal screening in high risk pregnancies
  • For the preimplantation genetic testing in an affected family member identified with the muscular dystrophies

Positive

At least one known pathogenic variant or mutation associated with muscular dystrophies should be detected. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants. CCTG repeats ~75-11,000 is considered pathogenic in Myotonic Dystrophy, Type II.

>50 CTG trinucleotide repeats are associated with disease manifestations in Myotonic Dystrophy, Type I. Identification of a heterozygous pathogenic contraction of the D4Z4 repeat array in the subtelomeric region of chromosome 4q35 on a chromosome 4 permissive haplotype in FSHD1.

Identification of hypomethylation of the D4Z4 repeat array in the subtelomeric region of chromosome 4q35 on a chromosome 4 permissive haplotype in FSHD2. Hypomethylation of the D4Z4 repeat array can be due to a heterozygous pathogenic variant in SMCHD1 or DNMT3B.

Negative

No pathogenic variant or mutation detected. ≤30 uninterrupted CCTG repeats in Myotonic Dystrophy, Type II. 5-34 CTG trinucleotide repeats in Myotonic Dystrophy, Type I. D4Z4 locus with any number of repeat units on a non-permissive haplotype.

Finding Result / Interpretation
Pathogenic variants or mutations analyzed Negative
Myotonic Dystrophy, Type II (CCTG repeats) <30 CCTG repeats
Myotonic Dystrophy, Type I (CTG trinucleotide repeats) 5-34 CTG trinucleotide repeats
D4Z4 locus Any number of repeat units on a non-permissive haplotype
Multiplex Ligation-Dependent Probe Amplification (MLPA), array comparative genomic hybridization (aCGH), Massively Parallel Sequencing, direct sequence analysis and/or next-generation sequencing (NGS), Conventional Sanger sequencing.

Whole blood (EDTA). 

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
Repeat Expansion Detection by PCR, Southern Blot deletion/duplication analysis, Muscle biopsy, Serum CK.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login